Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q1

7446.TEDINET S100Q8CO
Period2022-10-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥9.4bn2022-10-01 → 2022-12-31Cons.Net sales
Revenue¥37.3bn2021-10-01 → 2022-09-30Cons.Net sales (5-year summary)
Revenue¥9.0bn2021-10-01 → 2021-12-31Cons.Net sales
Operating income¥254m2022-10-01 → 2022-12-31Cons.Operating income
Operating income¥214m2021-10-01 → 2021-12-31Cons.Operating income
Ordinary income¥271m2022-10-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.0bn2021-10-01 → 2022-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥229m2021-10-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥271m2022-10-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥229m2021-10-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥182m2022-10-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥658m2021-10-01 → 2022-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥148m2021-10-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥187m2022-10-01 → 2022-12-31Cons.Profit loss
Net income¥155m2021-10-01 → 2021-12-31Cons.Profit loss
Total assets¥19.2bnat 2022-12-31Cons.Assets
Total assets¥17.5bnat 2022-09-30Cons.Assets
Total assets¥18.1bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥12.5bnat 2022-12-31Cons.Liabilities
Total liabilities¥10.8bnat 2022-09-30Cons.Liabilities
Net assets / equity¥6.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥6.7bnat 2022-09-30Cons.Net assets
Net assets / equity¥6.3bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥2.4bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥1.4bnat 2022-09-30Cons.Cash and deposits
EPS (basic)¥202.312022-10-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥728.762021-10-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.692021-10-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio34.7%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio37.7%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.6%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2022-10-01 → 2022-12-31¥17m
Otherother segmentsrevenue external2022-10-01 → 2022-12-31¥17m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue2022-10-01 → 2022-12-31¥866m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue external2022-10-01 → 2022-12-31¥866m
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue2022-10-01 → 2022-12-31¥4.6bn
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2022-10-01 → 2022-12-31¥4.6bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue2022-10-01 → 2022-12-31¥4.0bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2022-10-01 → 2022-12-31¥4.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-10-01 → 2022-12-31¥9.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-10-01 → 2022-12-31¥9.4bn
Otherother segmentsrevenue2021-10-01 → 2021-12-31¥20m
Otherother segmentsrevenue external2021-10-01 → 2021-12-31¥20m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2021-12-31¥823m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2021-12-31¥823m
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2021-12-31¥4.4bn
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2021-12-31¥4.4bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2021-12-31¥3.8bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2021-12-31¥3.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2021-12-31¥9.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2021-12-31¥9.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 369
ItemContextValueUnit
Gross profitPrior1YTDDuration_ReconcilingItemsMember－JPY
Gross profitPrior1YTDDuration839841000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02810-000PharmaceuticalProductsReportableSegmentsMember4570107000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02810-000ReagentForClinicalTestReportableSegmentsMember3956475000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02810-000FoodReportableSegmentsMember866100000JPY
Revenues from external customersCurrentYTDDuration_OtherReportableSegmentsMember16616000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember9409299000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration9409299000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02810-000PharmaceuticalProductsReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02810-000ReagentForClinicalTestReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02810-000FoodReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_OtherReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02810-000PharmaceuticalProductsReportableSegmentsMember4570107000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02810-000ReagentForClinicalTestReportableSegmentsMember3956475000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02810-000FoodReportableSegmentsMember866100000JPY
Net salesCurrentYTDDuration_OtherReportableSegmentsMember16616000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember9409299000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration9409299000JPY
Gross profitCurrentYTDDuration_jpcrp040300-q1r_E02810-000PharmaceuticalProductsReportableSegmentsMember394515000JPY
Gross profitCurrentYTDDuration_jpcrp040300-q1r_E02810-000ReagentForClinicalTestReportableSegmentsMember401706000JPY
Gross profitCurrentYTDDuration_jpcrp040300-q1r_E02810-000FoodReportableSegmentsMember64564000JPY
Gross profitCurrentYTDDuration_OtherReportableSegmentsMember8675000JPY
Gross profitCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember869460000JPY
Gross profitCurrentYTDDuration_ReconcilingItemsMember－JPY
Gross profitCurrentYTDDuration869460000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)東北財務局長
Filing date cover pageFilingDateInstant2023-02-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第72期第１四半期(自 2022年10月１日 至 2022年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)東北化学薬品株式会社
Company name in english cover pageFilingDateInstantTOHOKU CHEMICAL CO., LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　東　康之
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)青森県弘前市大字神田一丁目３番地の１
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)0172　(33)　8131　　　　(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)上席執行役員管理グループ長　磯辺　譲
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)青森県弘前市大字神田一丁目３番地の１
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)0172　(33)　8131　　　　(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)上席執行役員管理グループ長　磯辺　譲
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE02810
Fund codeFilingDateInstant－
Security codeFilingDateInstant74460
Filer name in japaneseFilingDateInstant
Original text (Japanese)東北化学薬品株式会社
Filer name in englishFilingDateInstantTOHOKU CHEMICAL CO.,LTD.

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-09-30pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass